Cargando…

Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States

We conducted a study to determine prevalence of HPV types in oropharyngeal cancers in the United States and establish a prevaccine baseline for monitoring the impact of vaccination. HPV DNA was extracted from tumor tissue samples from patients in whom cancer was diagnosed during 1995–2005. The sampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinau, Martin, Saraiya, Mona, Goodman, Marc T., Peters, Edward S., Watson, Meg, Cleveland, Jennifer L., Lynch, Charles F., Wilkinson, Edward J., Hernandez, Brenda Y., Copeland, Glen, Saber, Maria S., Hopenhayn, Claudia, Huang, Youjie, Cozen, Wendy, Lyu, Christopher, Unger, Elizabeth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012803/
https://www.ncbi.nlm.nih.gov/pubmed/24751181
http://dx.doi.org/10.3201/eid2005.131311
_version_ 1782314974233755648
author Steinau, Martin
Saraiya, Mona
Goodman, Marc T.
Peters, Edward S.
Watson, Meg
Cleveland, Jennifer L.
Lynch, Charles F.
Wilkinson, Edward J.
Hernandez, Brenda Y.
Copeland, Glen
Saber, Maria S.
Hopenhayn, Claudia
Huang, Youjie
Cozen, Wendy
Lyu, Christopher
Unger, Elizabeth R.
author_facet Steinau, Martin
Saraiya, Mona
Goodman, Marc T.
Peters, Edward S.
Watson, Meg
Cleveland, Jennifer L.
Lynch, Charles F.
Wilkinson, Edward J.
Hernandez, Brenda Y.
Copeland, Glen
Saber, Maria S.
Hopenhayn, Claudia
Huang, Youjie
Cozen, Wendy
Lyu, Christopher
Unger, Elizabeth R.
author_sort Steinau, Martin
collection PubMed
description We conducted a study to determine prevalence of HPV types in oropharyngeal cancers in the United States and establish a prevaccine baseline for monitoring the impact of vaccination. HPV DNA was extracted from tumor tissue samples from patients in whom cancer was diagnosed during 1995–2005. The samples were obtained from cancer registries and Residual Tissue Repository Program sites in the United States. HPV was detected and typed by using PCR reverse line blot assays. Among 557 invasive oropharyngeal squamous cell carcinomas, 72% were positive for HPV and 62% for vaccine types HPV16 or 18. Prevalence of HPV-16/18 was lower in women (53%) than in men (66%), and lower in non-Hispanic Black patients (31%) than in other racial/ethnic groups (68%–80%). Results indicate that vaccines could prevent most oropharyngeal cancers in the United States, but their effect may vary by demographic variables.
format Online
Article
Text
id pubmed-4012803
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-40128032014-05-09 Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States Steinau, Martin Saraiya, Mona Goodman, Marc T. Peters, Edward S. Watson, Meg Cleveland, Jennifer L. Lynch, Charles F. Wilkinson, Edward J. Hernandez, Brenda Y. Copeland, Glen Saber, Maria S. Hopenhayn, Claudia Huang, Youjie Cozen, Wendy Lyu, Christopher Unger, Elizabeth R. Emerg Infect Dis Research We conducted a study to determine prevalence of HPV types in oropharyngeal cancers in the United States and establish a prevaccine baseline for monitoring the impact of vaccination. HPV DNA was extracted from tumor tissue samples from patients in whom cancer was diagnosed during 1995–2005. The samples were obtained from cancer registries and Residual Tissue Repository Program sites in the United States. HPV was detected and typed by using PCR reverse line blot assays. Among 557 invasive oropharyngeal squamous cell carcinomas, 72% were positive for HPV and 62% for vaccine types HPV16 or 18. Prevalence of HPV-16/18 was lower in women (53%) than in men (66%), and lower in non-Hispanic Black patients (31%) than in other racial/ethnic groups (68%–80%). Results indicate that vaccines could prevent most oropharyngeal cancers in the United States, but their effect may vary by demographic variables. Centers for Disease Control and Prevention 2014-05 /pmc/articles/PMC4012803/ /pubmed/24751181 http://dx.doi.org/10.3201/eid2005.131311 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Steinau, Martin
Saraiya, Mona
Goodman, Marc T.
Peters, Edward S.
Watson, Meg
Cleveland, Jennifer L.
Lynch, Charles F.
Wilkinson, Edward J.
Hernandez, Brenda Y.
Copeland, Glen
Saber, Maria S.
Hopenhayn, Claudia
Huang, Youjie
Cozen, Wendy
Lyu, Christopher
Unger, Elizabeth R.
Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States
title Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States
title_full Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States
title_fullStr Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States
title_full_unstemmed Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States
title_short Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States
title_sort human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, united states
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012803/
https://www.ncbi.nlm.nih.gov/pubmed/24751181
http://dx.doi.org/10.3201/eid2005.131311
work_keys_str_mv AT steinaumartin humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT saraiyamona humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT goodmanmarct humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT petersedwards humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT watsonmeg humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT clevelandjenniferl humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT lynchcharlesf humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT wilkinsonedwardj humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT hernandezbrenday humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT copelandglen humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT sabermarias humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT hopenhaynclaudia humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT huangyoujie humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT cozenwendy humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT lyuchristopher humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT ungerelizabethr humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates
AT humanpapillomavirusprevalenceinoropharyngealcancerbeforevaccineintroductionunitedstates